IMMray™, the core technology of Immunovia, is based on in-house designed recombinant antibody microarrays. This unique, high-performing platform enables us to rapidly (within a few hours) profile all common clinical sample formats such as serum, plasma and urine, as well as tissue (tumor) extracts. The set-up deciphers the protein composition of the sample in a highly sensitive and specific manner, targeting numerous proteins in a single experiment. This opens up novel opportunities for biomarker discovery not matched by conventional proteomic technologies, which are known to suffer from low throughput as well as impaired resolution and sensitivity.
The concept of Immunovia’s recombinant antibody arrays is based on the dispensing of small amounts (picoliter scale) of individual antibodies in discrete positions in an ordered pattern (an array) onto a solid support where they act as specific catcher molecules.
Uniquely, Immunovia exploits the immune system as an early, specific and sensitive sensor for disease, which is why the set-up targets mainly, but exclusively, immunoregulatory proteins. These miniaturized arrays (<cm2), ranging in density from a few antibodies to several thousand, are then incubated with minute amounts (µL scale) of labeled non-fractionated biological sample, e.g. serum. Next, specifically bound proteins are detected and quantified, mainly using fluorescence as the mode of detection. Finally, the microarray images are transformed into protein expression profiles to reveal the composition of the sample at the molecular level.
Using state-of-the-art bioinformatics, this information can then be used to decipher condensed protein signatures (frequently < 25) or molecular fingerprints that reflect the target disease. Measuring the delineated biomarker panels ultimately provides clinicians with actionable information that enables early and specific diagnosis, prognosis and classification, for example, as well as monitoring patients for factors such as risk of relapse and response to treatment.